Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Exanthema / chemically induced
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Pigmentation Disorders / chemically induced*
  • Pigmentation Disorders / physiopathology
  • Piperazines / adverse effects*
  • Piperazines / therapeutic use*
  • Pyrimidines / adverse effects*
  • Pyrimidines / therapeutic use*

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate